Peptide compounding evidence stays thin for six peptides in HHS policy

WASHINGTON: Peptide compounding evidence remains thin for the six peptides a new federal policy lets licensed pharmacies make, according to a Men's Health guide published Oct. 29. The magazine reviewed research on 19 synthetic peptides and found that most support comes from animal work, cell studies or small human reports without control groups. None of the six is approved by the FDA. The guide reports no new data. It gathers the published record in one place as pharmacies begin to compound these products for patients with a prescription.

Panel vote and HHS policy set the stage

The FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026, at the agency's White Oak campus in Silver Spring, Maryland, according to the FDA meeting page. It weighed whether seven peptides should go on the 503A bulks list, the roster of bulk substances that licensed pharmacies may use to compound drugs. FDA reviewers judged each peptide against named uses, such as ulcerative colitis for BPC 157, wound healing for TB 500 and insomnia for epitalon. Men's Health reports that the FDA advisory committee backed six of the seven and voted against emideltide, a sleep peptide. It also reports that no vote was unanimous. Advisory committees give advice only, and the FDA says it is not legally bound to follow it.

In October, Health Secretary Robert F. Kennedy Jr. advanced a temporary policy covering the six peptides the panel backed, Men's Health reports. Under the HHS peptide policy, federal authorities will not penalize licensed pharmacists who compound and dispense BPC 157, TB 500, KPV, MOTS c, Semax or epitalon for patients with a prescription. The policy document requires pharmacists to report serious adverse events and product quality problems to the FDA and to the states where the drugs are made, the magazine says. Peptide Zone has covered the conditions attached to the policy in a separate report. Five more peptides are due for panel review in 2027, according to Men's Health, which expects a further five to stay restricted.

BPC 157 and TB 500 rest mostly on animal studies

BPC 157 is the best known peptide in the policy, and its record sits mostly in animals. Men's Health cites a 2025 review that searched for studies published between 1993 and 2024. Of those 36 studies, 35 were animal experiments and only one was carried out in humans. In animals, the review reported higher growth factor levels, less inflammation and better healing of muscle and other tissue. The single human study, from 2021, followed people injected for knee pain, some with BPC 157 alone and some with thymosin beta 4 added. Most reported less pain. The magazine notes that the study had no control group and relied on what patients recalled about their pain rather than an objective measure.

Of those 36 studies, 35 were animal experiments and only one was carried out in humans.

TB 500 is a synthetic peptide tied to thymosin beta 4, a protein that binds actin, a structural part of cells. Men's Health says there is a fair body of animal research on thymosin beta 4 and faster healing of skin and muscle, but few studies on TB 500 itself. It reports no clinical evidence in humans that either compound repairs muscle or improves athletic performance. The guide also points to studies that link high thymosin beta 4 levels to cancer. The concern is that the same process that helps wounds heal, the growth of new blood vessels, may also feed tumors. Users often take the two peptides together, a pairing the magazine says is known online as the Wolverine Stack.

Other panel peptides show limited human testing

The peptide compounding evidence for the other panel peptides is thinner still, by the magazine's account. Most Semax research comes from Russia, where it is used after stroke, and a review by the Alzheimer's Drug Discovery Foundation found little strong evidence that it helps cognition in healthy people. One review reported nasal discoloration and higher blood sugar in people with diabetes. Epitalon has not been tested in people for cognitive decline, and much of its early work came from one Russian laboratory. For KPV, the most cited study dates to 2008 and used human intestinal cells, not patients. MOTS c lacks clinical trial data, though Men's Health says a 12 week trial in adults with obesity and prediabetes is recruiting.

The guide also reviews peptides outside this year's vote, and two records stand out. AOD 9604, a fat loss candidate, failed to show significant weight loss in a 24 week phase 2 trial of 536 people in 2007, and its clinical development stopped, the magazine reports. The company that developed it funded all six of its clinical trials. For CJC 1295, a peptide that raises growth hormone, Men's Health cites a 2006 study in which 94 percent of people had side effects after a single injection, against 29 percent on placebo. A later phase 2 trial of CJC 1295 in people with obesity and HIV was stopped after a participant died. Neither peptide is covered by the current policy.

Doctors weigh access against missing safety data

Doctors quoted in the guide differ on what the policy means for patients. Sritha Rajupet, chair of family, population and preventive medicine at Stony Brook Medicine, told the magazine that "most of these peptides still lack high-quality human data on safety, effectiveness, and appropriate dosing." Internal medicine physician Motisola Lewis said her concern is that "the enthusiasm around peptides has moved much faster than the clinical evidence." She listed open questions: whether the peptides work and for whom, the quality of supply from third parties, and who is in charge of oversight. Jeff Cohen, cofounder of the American Peptide Association, welcomed the move in an email to Men's Health and called it "much needed clarity" for the industry.

Several points remain open. Men's Health does not say how long the temporary policy will last, and Peptide Zone has reported that a final rule is still pending. Rajupet said many people already get peptides through unregulated channels, and she urged open, nonjudgmental talks with patients that make clear the products remain experimental. Researchers writing in JAMA have argued that the panel vote could weaken drug approval at the FDA. Pharmacists and pharmacologists also split over the policy, with some calling it safer than the gray market. The gap in peptide compounding evidence means compounding status is not FDA approval and does not show that a peptide is safe or works.

Conclusion

The Men's Health guide adds no new trial results, but it sets out the peptide compounding evidence behind a policy now in effect. For BPC 157, TB 500 and four other peptides, the record is mostly animal work, cell studies and small uncontrolled human reports. Pharmacists must report serious harms to the FDA and the states. The next markers are any final FDA decision on the list and the 2027 panel review of five more peptides. This report is research news, not medical advice.